hero image
Ali Ataya - University of Florida. Gainesville, FL, US

Ali Ataya Ali Ataya

M.D./Associate Professor | University of Florida

Gainesville, FL, UNITED STATES

Dr. Ali Ataya's focus is on helping patients with rare lung diseases.


Dr. Ali Ataya is an associate professor within the Division of Pulmonary, Critical Care and Sleep Medicine. He is passionate about helping patients with rare lung diseases. Dr. Ataya's area of expertise is pulmonary hypertension and rare lung disorders.

Areas of Expertise (6)

ICU Ventilator Weaning

Pulmonary Alveolar Proteinosis

Rare Lung Diseases

Pulmonary Arterial Hypertension


Hereditary Hemorrhagic Telangiectasia

Media Appearances (3)

Unvaccinated, expectant mother nearly dies of COVID-19, becomes vaccine champion

UF Health  online


Friends and family gathered at Amy Westman’s July 24 baby shower. Gifts and balloons and bursts of blue brightened the room. Blue cupcakes. Blue bows and wrapping paper. Blue as in boy. Her lovely Nicholas. Amy didn’t give much thought to the coronavirus at the shower. Nicholas was six weeks from his due date. This was a happy time. All these months into the pandemic and she hadn’t gotten sick. Besides, the coronavirus seemed at low ebb.

view more

UF Health among first in world to use novel diaphragmatic pacer to help COVID-19 patients breathe

UF Health  online


As the world’s focus shifts from COVID-19 vaccine creation to distribution, researchers and clinicians continue to search for ways to alleviate the suffering of patients and the demands on crowded hospitals. Now, after Emergency Use Authorization approval from the U.S. Food and Drug Administration, University of Florida Health is the first in the Southeast to implant a novel diaphragmatic neurostimulator in a coronavirus patient requiring a ventilator. This is the third instance of this here in the United States.

view more

UF Health earns accreditation as clinic site to treat rare lung disease

UF Health  online


The University of Florida College of Medicine’s division of pulmonary, critical care & sleep medicine was recently named the third accredited LAM and Rare Lung Disease clinic site in Florida by the LAM Foundation. The site, which is led by director Mark Brantly, M.D., a professor of medicine, and associate director Ali Ataya, M.D., an assistant professor of medicine, will focus on patients with orphan lung diseases.

view more

Articles (2)

The Role of GM-CSF Autoantibodies in Infection and Autoimmune Pulmonary Alveolar Proteinosis: A Concise Review

Frontiers in Immunology

Ali Ataya, et al.


Autoantibodies to multiple cytokines have been identified and some, including antibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF), have been associated with increased susceptibility to infection. High levels of GM-CSF autoantibodies that neutralize signaling cause autoimmune pulmonary alveolar proteinosis (aPAP), an ultrarare autoimmune disease characterized by accumulation of excess surfactant in the alveoli, leading to pulmonary insufficiency. Defective GM-CSF signaling leads to functional deficits in multiple cell types, including macrophages and neutrophils, with impaired phagocytosis and host immune responses against pulmonary and systemic infections. In this article, we review the role of GM-CSF in aPAP pathogenesis and pulmonary homeostasis along with the increased incidence of infections (particularly opportunistic infections). Therefore, recombinant human GM-CSF products may have potential for treatment of aPAP and possibly other infectious and pulmonary diseases due to its pleotropic immunomodulatory actions.

view more

Therapeutic Challenges and Emerging Treatment Targets for Pulmonary Hypertension in Left Heart Disease

Journal of the American Heart Association

Christelle Lteif, Ali Ataya and Julio D. Duarte


Pulmonary hypertension (PH) attributable to left heart disease (LHD) is believed to be the most common form of PH and is strongly associated with increased mortality and morbidity in this patient population. Specific therapies for PH‐LHD have not yet been identified and the use of pulmonary artery hypertension‐targeted therapies in PH‐LHD are not recommended. Endothelin receptor antagonists, phosphodiesterase‐5 inhibitors, guanylate cyclase stimulators, and prostacyclins have all been studied in PH‐LHD with conflicting results

view more





Dr. Ali Ataya loading image



Languages (1)

  • English